Recombinant adeno-associated virus 2 (rAAV2) has been shown to deliver genes to
neurons effectively in the brain, retina, and spinal cord. The characterization of new AAV …

In recent years, adeno-associated virus (AAV) has become the most important vector for
central nervous system (CNS) gene therapy. AAV has already shown promising results in …

Gene therapy using recombinant adeno-associated viral (AAV) vectors is emerging as a
promising approach to treat central nervous system disorders such as Spinal muscular …

There is strong interest in developing practical strategies for gene delivery to the central
nervous system (CNS). Direct delivery into the brain or spinal cord is highly invasive as well …

Vectors derived from adeno-associated virus (AAV) are promising candidates for neural cell
transduction in vivo because they are nonpathogenic and achieve long-term transduction in …

We examined the transduction efficiency of different adeno-associated virus (AAV) capsid
serotypes encoding for green fluorescent protein (GFP) flanked by AAV2 inverted terminal …

Intracerebral administration of recombinant adeno-associated vector (AAV) has been
performed in several clinical trials. However, delivery into the brain requires multiple …

Delivery of genes to the brain and spinal cord across the blood-brain barrier (BBB) has not
yet been achieved. Here we show that adeno-associated virus (AAV) 9 injected …

A limitation for recombinant adeno-associated virus (rAAV)-mediated gene transfer into the
central nervous system (CNS) is the low penetration of vectors across the human blood …

Targeting lower motor neurons (LMNs) for gene delivery could be useful for disorders such
as spinal muscular atrophy and amyotrophic lateral sclerosis. LMNs reside in the ventral …